



1,000 radiation therapy centers choose myQA®

myQA® has been selected by 1,000 customers around the world as their trusted global QA platform to integrate quality assurance applications, people, and know-how.

Schwarzenbruck, July 26, 2017 – IBA (Ion Beam Applications S.A.), the world's leading provider of proton therapy solutions and radiation therapy integrated quality assurance (QA) for the treatment of cancer, announced that it has reached the 1,000 myQA® customers milestone worldwide. Since the first release of myQA in 2015, IBA has rapidly built its customer base across the global radiation therapy community and today serves the largest QA platform customer base by far. This growth has been driven by the need to improve the integration of quality assurance across all QA applications, departments, and professionals in radiation therapy and beyond.

With myQA, IBA Dosimetry has been the innovation leader for quality assurance platform solutions and has set a new standard in making quality checks for cancer treatments safer and more efficient. Compared to other solutions, myQA integrates all modern radiation therapy QA needs, from Beam Scanning and Machine QA, to Imaging QA and Patient QA. The Generic Test functionality enables users to integrate their individual site specific tests into the global QA platform

*"We are proud to announce the milestone of 1,000 myQA customers since we released the global QA platform in March 2015. This is the proof that IBA Dosimetry has been leading the innovation to integrate quality assurance." says **Andreas Stempfli, Global Brand Manager myQA at IBA Dosimetry**. He continues, "With this impressive customer base we are connecting medical physicists and radiation therapy experts around the world to drive further innovations and safer patient treatment. At the upcoming AAPM meeting our customers will be able to see the latest enhancements of myQA."*

About myQA® Global QA Platform

The myQA software platform connects QA applications, people, and know-how through a Central Database, as well as dedicated site-to-site QA benchmarking options. It offers full support to its users by integrating the entire QA workflow, and provides access to all software application modules and data from one intuitive interface. Users also have a complete, instant overview of their results with the myQA Cockpit. myQA integrates all major tasks of the QA workflow, from Beam Scanning and Machine QA, to Imaging QA and Patient QA. Furthermore, users can also integrate their individual hospital tests into myQA.

myQA integrates colleagues and sites by providing access to QA data and applications from one central software platform and one central database. myQA further enables anonymous benchmarking of individual QA results with hundreds of other QA data from around the world.

For more information visit <https://www.iba-dosimetry.com/solutions/myqa/>



About IBA Dosimetry

IBA Dosimetry GmbH innovates radiation therapy, proton therapy and diagnostic imaging through integrated Quality Assurance solutions that are efficient, intuitive and that provide peace of mind for healthcare professionals and patients around the world. The myQA® Global QA Platform is the backbone for Integrated Quality Assurance solutions. IBA Dosimetry has more than 220 international employees in four offices in Germany, France, China and USA.

Find more information at: www.iba-dosimetry.com

About IBA

IBA (Ion Beam Applications S.A.) is a global medical technology company focused on bringing integrated and innovative solutions for the diagnosis and treatment of cancer. The company is the worldwide technology leader in the field of proton therapy, considered to be the most advanced form of radiation therapy available today. IBA's proton therapy solutions are flexible and adaptable, allowing customers to choose from universal full-scale proton therapy centers as well as compact, single room solutions. In addition, IBA also has a radiation dosimetry business and develops particle accelerators for the medical world and industry. Headquartered in Belgium and employing about 1,500 people worldwide, IBA has installed systems across the world.

IBA is listed on the pan-European stock exchange NYSE EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB). More information can be found at: www.iba-worldwide.com

Contact:

Ralf Schira

Vice President Marketing

IBA Dosimetry

ralf.schira@iba-dosimetry.com

<http://www.iba-dosimetry.com/>